Pharmac boss backs Herceptin decision

August 10, 2008

Pharmac chief Matthew Brougham explains the reasoning behind the decision to not fund 12 month courses of Herceptin.

He says that if one of his family had breast cancer he would recommend she take the nine week course which is publicly funded and that the jury is still out on the benefits of the year-long course.

The Herald editorial supports the decision and says that even if Pharmac had more money it would probably not spend it on longer courses of Herceptin.

And Kerre Woodham agrees that there is not enough evidence for Phramac to have reversed its decision to fund only nine weeks of the drug.

Update: Macdoctor responds to the Herald.


Why can’t we afford Herceptin?

August 7, 2008

Pharmac’s announcement it won’t fund 12 month courses of Herceptin for women with aggressive Her-2 breast cancer has been labelled a cruel blow by Breast Cancer Aotearoa Coalition chair, Libby Burgess.

Ms Burgess said it was “unbelieveable and shameful” that New Zealand women were denied the standard of care offered elsewhere.

“It’s a bad outcome, but we’re not terribly surprised by it. But we are of course extremely disappointed.

“This is a cruel blow for women and their families. Phamac’s continuing refusal to fund the treatments New Zealanders need is simply inhumane.”
 
Ms Burgess said that, to access the 12 month treatment their doctors were recommending, women had to fundraise the tens of thousands of dollars needed. 

“This adds huge stress and suffering for women when they most need support and comfort … I am amazed Government hasn’t stepped in to end this inhumane treatment of our women.

“Increased funding for medicines including Herceptin will surely become an election issue. That will give voters the opportunity to decide.

Pharmac chief executive Matthew Brougham said the cost wasn’t the reason the drug won’t be funded.

“I want to be absolutely clear; this decision is not about the cost of Herceptin. This decision rests solely on the science and our assessment, our confidence, around whether or not funding 12 months treatment with Herceptin would produce additional health benefits.”

But he also said:

[Pharmac]  had to consider all illnesses and treatments, not just cancer, and had to make a decision with limited funds about what would bring the greatest benefits.

“It’s not about who can scream the loudest and make the most noise.” Read the rest of this entry »


%d bloggers like this: